NCT06257420View on ClinicalTrials.gov

Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

Enrolling by invitationOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

December 11, 2023

Primary Completion Date

December 11, 2025

Study Completion Date

June 11, 2026

Conditions
Myalgic EncephalomyelitisLong-COVID
Interventions
DRUG

Rapamycin

Once weekly oral rapamycin

Trial Locations (5)

55905

The Mayo Clinic, Rochester

84102

Bateman Horne Center, Salt Lake City

89451

Sierra Internal Medicine, Incline Village

94040

Center For Complex Diseases, Palo Alto

98109

Center For Complex Diseases, Seattle

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Center For Complex Diseases-Seattle, WA

UNKNOWN

collaborator

Sierra Internal Medicine, Incline Village, NV

UNKNOWN

collaborator

Center for Complex Diseases- Palo Alto, CA

UNKNOWN

collaborator

Simmaron Research Inc. R&D Lab, University of Wisconsin, Milwaukee (UWM)

UNKNOWN

collaborator

Bateman Horne Center, Salt Lake City, UT

UNKNOWN

collaborator

Mayo Clinic

OTHER

lead

Simmaron Research Inc.

OTHER